Company Analysis
Sign in

Lifecore Biomedical, Inc. (LFCR)

Nasdaq: LFCR · Pharmaceutical Preparations · Chaska, MN · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.1
◀ Past 4.2● Present 4.2▶ Future 3.9
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$129M+0.5%
Net income-$38.7M-422.3%
Earnings per share$-1.27-484.8%
Operating cash flow-$206,000-180.2%
Cash$8.3M-2.3%
Debt$130M+4.6%
Shareholders’ equity$1.3M-88.2%
Shares, diluted34.8M-5.0%
Return on equityn/a
The recordfrom its filings
Filings in 202638
Newest filingNov 5 · DEFA14A
Annual reportMar 16, 2026
Quarterly reportNov 4, 2026
Next report due10-KT by Mar 16
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted46
Filer categoryAccelerated filer<br>Smaller reporting company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 29, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 28, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Sep 28, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton LFCR · research, not advice